**Appendix**

A screenshot of a cell phone

Description automatically generated

**Appendix 1 – Average baseline demographics across all trials, and split into those trials done using boosted and unboosted TDF regimens**

**![A screenshot of a cell phone

Description automatically generated]()**

**Appendix 2 – Meta-analysis of efficacy**

A screenshot of a cell phone

Description automatically generated

**Appendix 3 – all grade 1-4 adverse events meta analysis**

- including events/people expect advance = people/people

![A screenshot of a cell phone

Description automatically generated]()

**Appendix 4 – meta-analysis of grade 3/4 adverse events**

![A screenshot of a cell phone

Description automatically generated]()

**Appendix 5 – Grade 3-4 laboratory adverse events**

![A screenshot of a cell phone

Description automatically generated]()

**Appendix 6 – meta-analysis of serious adverse events**

![A screenshot of a cell phone

Description automatically generated]()

**Appendix 7 – meta-analysis of discontinuations due to adverse events (D/CAE)**

![A screenshot of a cell phone

Description automatically generated]()

**Appendix 8 – meta-analysis of number of deaths from any cause**

![A screenshot of a cell phone

Description automatically generated]()

**Appendix 9 – discontinuations due to bone adverse events**

![A screenshot of a cell phone

Description automatically generated]()

**Appendix 10 - Forest plot showing details of bone fractures - again divided by boosted and unboosted**

A screenshot of a cell phone

Description automatically generated

**Appendix 11. Forest plot showing details of meta-analysis for discontinuations for renal adverse events, divided by boosted and unboosted.**

![A screenshot of a cell phone

Description automatically generated]()

**Appendix 11 – renal tubular adverse events**